Joint effect of stroke and APOE 4 on dementia risk: The Canadian Study of Health and Aging

Neurology

Volumn 70, Issue 1, 2008, Pages 9-16

  Jin, Y P ^a   Ostbye T ^b   Feightner, J W ^a   Di Legge, S ^a,c   Hachinski, V ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; AGING; ARTICLE; CLINICAL EXAMINATION; CONFIDENCE INTERVAL; CONTROL GROUP; CONTROLLED STUDY; DEMENTIA; DISEASE SEVERITY; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SCREENING TEST; STROKE; STROKE PATIENT;

EID: 37849053122     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000284609.77385.03     Document Type: Article

References (33)

1. Tatemichi TK, Desmond DW, Mayeux R, et al. Dementia after stroke: baseline frequency, risks, and clinical features in a hospitalized cohort. Neurology 1992;42:1185-1193.
2. Kokmen E, Whisnant JP, O'Fallon WM, Chu CP, Beard CM. Dementia after ischemic stroke: a population-based study in Rochester, Minnesota (1960-1984). Neurology 1996;46:154-159.
3. Henderson AS, Easteal S, Jorm AF, et al. Apolipoprotein E allele epsilon 4, dementia, and cognitive decline in a population sample. Lancet 1995;346:1387-1390.
4. Myers RH, Schaefer E, Wilson PW, et al. Apolipoprotein E epsilon4 association with dementia in a population-based study: the Framingham study. Neurology 1996;46:673-677.
5. Hsiung GY, Sadovnick AD, Feldman H. Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging. CMAJ 2004;171:863-867.
6. Kalmijn S, Feskens EJ, Launer LJ, Kromhout D. Cerebrovascular disease, the apolipoprotein e4 allele, and cognitive decline in a community-based study of elderly men. Stroke 1996;27:2230-2235.
7. Dik MG, Deeg DJ, Bouter LM, Corder EH, Kok A, Jonker C. Stroke and apolipoprotein E epsilon4 are independent risk factors for cognitive decline: a population-based study. Stroke 2000;31:2431-2436.
8. Zhu L, Fratiglioni L, Guo Z, et al. Incidence of dementia in relation to stroke and the apolipoprotein E epsilon4 allele in the very old: findings from a population-based longitudinal study. Stroke 2000;31:53-60.
9. Jin YP, Di Legge S, Ostbye T, Feightner JW, Hachinski V. The reciprocal risks of stroke and cognitive impairment in an elderly population. Alzheimer's & Dementia 2006;2:171-178.
10. The Canadian Study of Health and Aging Working Group. Canadian Study of Health and Aging: study methods and prevalence of dementia. CMAJ 1994;150:899-913.
11. Graham JE, Rockwood K, Beattie BL, et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet 1997;349:1793-1796.
12. Teng EL, Chui HC. The Modified Mini-Mental State (3MS) Examination. J Clin Psychiatry 1987;48:314-318.
13. Eastwood R, Nobbs H, Lindsay J, et al. Canadian Study of Health and Aging. Dementia 1992;3:209-212.
14. Bland RC, Newman SC. Mild dementia or cognitive impairment: the Modified Mini-Mental State Examination (3MS) as a screen for dementia. Can J Psychiatry 2001;46:506-510.
15. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed., revised. Washington, DC: American Psychiatric Association, 1987.
16. Jin YP, Di Legge S, Ostbye T. Is self-reported stroke history reliable in elderly with cognitive impairment? A community-based study. Abstract book for the 58th Annual Meeting of the American Academy of Neurology; April 1-8, 2006; San Diego, California. Abstract P05.165.
17. Botto LD, Khoury MJ. Commentary: facing the challenge of gene-environment interaction: the two-by-four table and beyond. Am J Epidemiol 2001;153:1016-1020.
18. Szklo M, Javier Nieto F. Defining and assessing heterogeneity of effects: interaction. In: Szklo M, Javier Nieto F, eds. Epidemiology: Beyond the basics. Gaithersburg, Maryland: Aspen Publishers, 2000:177-253.
19. Leys D, Henon H, Mackowiak-Cordoliani MA, Pasquier F. Poststroke dementia. Lancet Neurol 2005;4:752-759.
20. Desmond DW, Moroney JT, Sano M, Stern Y. Incidence of dementia after ischemic stroke: results of a longitudinal study. Stroke 2002;33:2254-2260.
21. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-1472.
22. Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol 2006;5:735-741.
23. Holtzman DM. In vivo effects of ApoE and clusterin on amyloid-beta metabolism and neuropathology. J Mol Neurosci 2004;23:247-254.
24. Strittmatter WJ, Weisgraber KH, Huang DY, et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993;90:8098-8102.
25. Beffert U, Cohn JS, Petit-Turcotte C, et al. Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent. Brain Res 1999;843:87-94.
26. Strittmatter WJ, Saunders AM, Goedert M, et al. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci USA 1994;91:11183-11186.
27. Tesseur I, Van Dorpe J, Spittaels K, Van den Haute C, Moechars D, Van Leuven F. Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. Am J Pathol 2000;156:951-964.
28. Handelmann GE, Boyles JK, Weisgraber KH, Mahley RW, Pitas RE. Effects of apolipoprotein E, beta-very low density lipoproteins, and cholesterol on the extension of neurites by rabbit dorsal root ganglion neurons in vitro. J Lipid Res 1992;33:1677-1688.
29. Teter B. ApoE-dependent plasticity in Alzheimer's disease. J Mol Neurosci 2004;23:167-179.
30. Prince M, Lovestone S, Cervilla J, et al. The association between APOE and dementia does not seem to be mediated by vascular factors. Neurology 2000;54:397-402.
31. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease: the Nun Study. JAMA 1997;277:813-817.
32. Rothman KJ, Greenland S. Introduction to categorical statistics. In: Rothman KJ, Greenland S, eds. Modern epidemiology. 2nd ed. Philadelphia: Lippincott-Raven, 1998:244-245.
33. Qiu C, Kivipelto M, Aguero-Torres H, Winblad B, Fratiglioni L. Risk and protective effects of the APOE gene towards Alzheimer's disease in the Kungsholmen project: variation by age and sex. J Neurol Neurosurg Psychiatry 2004;75:828-833.